The main interest in our laboratory has been focused on the mechanisms of damage of some parasitic infections of public health problem in Mexico. The amebiasis is an infectious disease produced by the protozoan parasite Entamoeba histolytica. One of the interests has been the study of humoral and cellular immune responses (natural and specific immunities) and the cell changes produced during the host-parasite interaction in the intestine and the amebic liver abscess development. Using in vivo animal models of susceptibility and resistance to the disease, we are currently analyzing the role of several lectins and other molecules (cytokines, nitric oxide, oxidative stress, etc.) during the evolution of the lesions produced by E. histolytica. Moreover, our studies on the innate and specific immune responses have been related with the induction of protection against the infection.
Another important research line has been related with Free Living Amebas, especially Naegleria fowleri and Acanthamoeba spp. These amebas produce diverse types of human diseases, including the Primary Amebic Meningoencephalitis, Granulomatous Encephalitis and Amebic Keratitis (damage in the cornea). In our laboratory we have established in vivo animal models to determine the pathogenesis of the Amebic Keratitis and the Primary Amebic Meningoencephalitis. In these studies we are currently using different and new (molecular and cell biology, among others) methodologies that facilitate our understanding of the mechanisms of tissue invasion and damage. Our interest has been also focused on the role of the innate and specific responses that are involved in these infections.
In relation with chronic degenerative diseases, we are interested in the experimental liver cirrhosis and cancer liver. We are presently studying the role of inflammatory cells and reactive oxygen species (ROS) during the evolution of these important diseases. Using an experimental animal model (rat) we evaluate different anti-cirrhotic drugs that could be protect the liver as candidate for further treatment in humans